Validation of MMS Test for Cancer Monitoring

Melanoma Clinical Trial

— MMS-TM  

Official title:

Validation of MMS Test to Detect Active Tumor Growth of Different Cancer Types Before and After Therapy, as Well as for Subsequent Relapse Control in Comparison to Conventional Methods

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02113683
• Other study ID #: MMS-tm14
• Status: Terminated
• Start date: May 2014
• Est. completion date: June 20, 2018

Study information

• Verified date: March 2018
• Source: MedInnovation GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is the validation of MMS test to detect active tumor growth in different cancer types before and after therapy, as well as in the course of therapy and for subsequent relapse control compared to standard methods (clinical examination, imaging, tumor markers). It should be consider whether the MMS test has comparable diagnostic accuracy, and thus can replace more expensive or invasive procedures in future.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 100
• Est. completion date: June 20, 2018
• Est. primary completion date: June 20, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of colo-rectal cancer

• Clinical diagnosis of stomach cancer

• Suspected diagnosis of melanoma

Exclusion Criteria:

• Colitis ulcerosa

• Morbus Crohn

• Cancer in time period two years before

• Cancer therapy in time period two years before

Related Conditions & MeSH terms

• Colo-rectal Cancer
• Colorectal Neoplasms
• Melanoma
• Rectal Neoplasms
• Sarcoma
• Stomach Cancer
• Stomach Neoplasms

Locations

Country	Name	City	State
Germany	HELIOS Klinikum Berlin-Buch, Klinik für Interdisziplinäre Onkologie	Berlin

Sponsors (2)

Lead Sponsor	Collaborator
MedInnovation GmbH	HELIOS Klinikum Berlin-Buch

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	active tumor growth before and after cancer therapy		up to 36 month